Starpharma Holdings Limited (AU:SPL) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Starpharma Holdings Limited’s DEP® SN38 shows promising results in treating advanced colorectal and ovarian cancers, as presented at a recent cancer conference. The drug demonstrated sustained disease control and improved quality of life for patients with reduced toxicity compared to standard treatments. These promising Phase 1/2 trial results position DEP® SN38 as a strong candidate for further development and potential commercialization.
For further insights into AU:SPL stock, check out TipRanks’ Stock Analysis page.